Cancer therapeutics : experimental and clinical agents
Author(s)
Bibliographic Information
Cancer therapeutics : experimental and clinical agents
(Cancer drug discovery and development)
Humana, c1997
Available at 3 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references and index
Description and Table of Contents
Description
Cancer drug discovery has been and continues to be a process of ingenuity, serendip ity, and dogged determination. In an effort to develop and discover better therapies against cancer, investigators all over the world have increased our knowledge of cell biology, biochemistry, and molecular biology. The goal has been to define therapeuti cally exploitable differences between normal and malignant cells. The result has been an increased understanding of cellular and whole-organism biology and an increased respect for the flexibility and resiliency ofbiologically systems. Thus, as some new therapeutic targets have been defined and new therapeutic strategies have been attempted, so have some new biological hurdles resulting from tumor evasion of the intended therapeutic attack been discovered. Historically, anticancer drugs have originated from all available chemical sources. Synthetic molecules from the chemical industry, especially dyestuffs and warfare agents, and natural products from plants, microbes, and fungi have all been potential sources of pharmaceuticals, including anticancer agents. There is no shortage of molecules; the challenge has been and continues to be methods of identifying molecules that have the potential to be therapeutically important in human malignant disease. "Screening" remains the most important and most controversial method in cancer drug discovery. In vitro screens have generally focused on cytotoxicity and have identified several highly cytotoxic molecules. Other endpoints available in vitro are inhibition of proliferation, 3 inhibition of [ H]thymidine incorporation into DNA and various viability assays, based most frequently on dye exclusion or metabolism.
Table of Contents
Part I. Cytotoxic Agents: Old and New. Nitrogen Mustards, Gerald J. Goldenberg and Malcolm J. Moore. Phosphoramide and Oxazaphosphorine Mustards, Joel E. Wright. Development of the Nitrosoureas, David B. Ludlum. Platinum Complexes, Lloyd R. Kelland. Anthracyclines, Trevor W. Sweatman and Mervyn Israel. Topoisomerase I Inhibitors, Beppino C. Giovanella. DNA Topoisomerase II Inhibitors, Yves Pommier. The Taxoids, Marie-Christine Bissery and Francois Lavelle. Sequence-Selective Groove Binders, Franco Zunino and Giovanni Capranico. Bis-Naphthalimides: Synthesis and Preclinical Evaluation, Cynthia A. Romerdahl and Miguel F. Brana. Part II. Newer Strategies and Targets. The Enediynes, Nina Felice Schor. Matrix Metalloproteinase Inhibitors, William G. Stetler-Stevenson. Interferons and Other Cytokines, Jill A. Hendrzak and Michael J. Brunda. Discovery of TNP-470 and Other Angiogenesis Inhibitors, Donald E. Ingber. Antisense Oligonucleotides, Stanley T. Crooke. Growth Factors and Growth Factor Inhibitors, Edward A. Sausville and Dan L. Longo. Immunoconjugates, Walter A. Blattler, Ravi V. J. Chari, and John M. Lambert. A Case for ras Targeted Agents as Antineoplastics, Judith S. Sebolt-Leopold. Gene Therapy, Peter I. Schrier and Susanne Osanto. Index.
by "Nielsen BookData"